deGraffenried L - Search Results

1

FASN inhibition as a potential treatment for endocrine-resistant breast cancer.

Gruslova A, McClellan B, Balinda HU, Viswanadhapalli S, Alers V, Sareddy GR, Huang T, Garcia M, deGraffenried L, Vadlamudi RK, Brenner AJ. Gruslova A, et al. Among authors: degraffenried l. Breast Cancer Res Treat. 2021 Jun;187(2):375-386. doi: 10.1007/s10549-021-06231-6. Epub 2021 Apr 24. Breast Cancer Res Treat. 2021. PMID: 33893909

2

Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity.

DeGraffenried LA, Friedrichs WE, Fulcher L, Fernandes G, Silva JM, Peralba JM, Hidalgo M. DeGraffenried LA, et al. Ann Oncol. 2003 Jul;14(7):1051-6. doi: 10.1093/annonc/mdg291. Ann Oncol. 2003. PMID: 12853346 Free article.

3

Regulation of the estrogen receptor alpha minimal promoter by Sp1, USF-1 and ERalpha.

deGraffenried LA, Hopp TA, Valente AJ, Clark RA, Fuqua SA. deGraffenried LA, et al. Breast Cancer Res Treat. 2004 May;85(2):111-20. doi: 10.1023/B:BREA.0000025398.93829.78. Breast Cancer Res Treat. 2004. PMID: 15111769

4

NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen.

deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW, Weiss GR. deGraffenried LA, et al. Ann Oncol. 2004 Jun;15(6):885-90. doi: 10.1093/annonc/mdh232. Ann Oncol. 2004. PMID: 15151944 Free article.

5

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M. deGraffenried LA, et al. Clin Cancer Res. 2004 Dec 1;10(23):8059-67. doi: 10.1158/1078-0432.CCR-04-0035. Clin Cancer Res. 2004. PMID: 15585641

6

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.

Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA. Beeram M, et al. Among authors: degraffenried la. Ann Oncol. 2007 Aug;18(8):1323-8. doi: 10.1093/annonc/mdm170. Ann Oncol. 2007. PMID: 17693645 Free article.

7

Akt-induced tamoxifen resistance is associated with altered FKHR regulation.

Silva J, Cavazos DA, Donzis E, Friedrichs WE, Marciniak R, deGraffenried LA. Silva J, et al. Cancer Invest. 2007;25(7):569-73. doi: 10.1080/07357900701513538. Cancer Invest. 2007. PMID: 17952739

8

Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression.

Friedrichs W, Ruparel SB, Marciniak RA, deGraffenried L. Friedrichs W, et al. Among authors: degraffenried l. Nutr Cancer. 2011;63(5):771-7. doi: 10.1080/01635581.2011.570892. Epub 2011 Jun 11. Nutr Cancer. 2011. PMID: 21667400

9

Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer.

Tiwary R, Yu W, deGraffenried LA, Sanders BG, Kline K. Tiwary R, et al. Breast Cancer Res. 2011;13(6):R120. doi: 10.1186/bcr3063. Epub 2011 Nov 24. Breast Cancer Res. 2011. PMID: 22115051 Free PMC article.

10

The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001.

De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, Degraffenried LA, Hursting SD. De Angel RE, et al. Mol Carcinog. 2013 Jun;52(6):446-58. doi: 10.1002/mc.21878. Epub 2012 Jan 30. Mol Carcinog. 2013. PMID: 22290600

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters